Arrowhead Pharmaceuticals (ARWR) Downgraded to “Hold” at BidaskClub

BidaskClub downgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a buy rating to a hold rating in a research note published on Saturday morning.

Several other equities analysts have also recently weighed in on ARWR. Jefferies Group restated a hold rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, August 4th. ValuEngine upgraded Arrowhead Pharmaceuticals from a strong sell rating to a sell rating in a research note on Thursday, August 24th. Cantor Fitzgerald restated a hold rating and set a $2.00 price objective (up from $1.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, September 15th. Chardan Capital restated a neutral rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, September 13th. Finally, William Blair upgraded Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a research note on Monday, September 18th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Arrowhead Pharmaceuticals presently has an average rating of Hold and an average target price of $3.17.

Arrowhead Pharmaceuticals (ARWR) opened at $3.33 on Friday. The company has a quick ratio of 3.84, a current ratio of 3.84 and a debt-to-equity ratio of 0.03. Arrowhead Pharmaceuticals has a 52 week low of $1.20 and a 52 week high of $4.54.

Large investors have recently modified their holdings of the business. UBS Asset Management Americas Inc. lifted its stake in Arrowhead Pharmaceuticals by 414.7% during the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 53,500 shares in the last quarter. Virtu KCG Holdings LLC raised its stake in shares of Arrowhead Pharmaceuticals by 115.6% during the 2nd quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 53,215 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Arrowhead Pharmaceuticals by 252.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 31,765 shares during the period. LMR Partners LLP bought a new stake in shares of Arrowhead Pharmaceuticals during the 2nd quarter worth $467,000. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Arrowhead Pharmaceuticals by 10.4% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after purchasing an additional 16,103 shares during the period. Institutional investors and hedge funds own 20.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Arrowhead Pharmaceuticals (ARWR) Downgraded to “Hold” at BidaskClub” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/06/arrowhead-pharmaceuticals-arwr-downgraded-to-hold-at-bidaskclub.html.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply